Clinical trial NCT04735198: Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.
Official title: Effectiveness of Prophylactic Cholecystectomy in Patients With Midgut Neuroendocrine Tumor (Jejunum, Ileum or Proximal Colon) Who Require Primary Tumor Surgery. Randomized, Proof of Concept Clinical Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Midgut Carcinoid Tumor
Biliary Stones
Keywords: Neuroendocrine tumor
prophylactic cholecystectomy
Biliary stone disease
Lead sponsor: Hospital Universitari de Bellvitge
Sponsor class: OTHER
First posted: 2021-02-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators want to study the effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery. When patients are diagnosed and are tributary to surgical treatment, the tumor might compromise vascularization, and patients need an extensive bowel resection. The patients might also receive medical treatment with somatostatin analogs. The combination of extensive bowel resection and medical treatment might increase gallbladder stones, but patients might not develop biliary stone disease, as in the general population, where 20% of the population have gallbladder stones but only a 10 to 15 % of the population will develop symptoms.

The idea comes from the lack of literature about the incidence of biliary Stone disease in patients with midgut NET tumors.

It's a multicentric, open-label and randomized clinical trial to evaluate the incidence of biliary stone disease in patients with midgut NET who require primary tumor surgery combined or not to cholecystectomy.

Our hypothesis suggests that patients with midgut neuroendocrine tumor who require primary tumor resection without the combination of prophylactic cholecystectomy do not have an increased incidence of biliary stone disease two years after the surgery, regardless of treatment with SSA.

Detailed description: Title: Effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery. Randomized, proof of concept clinical trial.

Background: The prevalence of midgut NET has increased due to advances in diagnostic tests and its indolent course. When patients are diagnosed, they might be tributary to surgical treatment requiring an extensive bowel resection, and medical treatment with somatostatin analogs. Both treatments are related with gallbladder stone formation. The ENETS and NANETs recommend prophylactic cholecystectomy in patients with midgut NET who require primary tumor surgery, However, there is a lack of scientific evidence reinforcing this recommendation.

Objectives: The main objective is to evaluate the cumulated incidence rate of biliary stone disease in patients with midgut NET who require primary tumor resection, two years after the surgery.

Design: It's a multicentric, open-label and randomized clinical trial. Patients will be recruited from the General Surgery Services of the six Hospitals participating in the study. Patients must fullfill inclusion and exclusion criteria.

It is expected to recruit a maximum of one hundred patients in two years (50 per group). Patients will be randomly assigned into the Experimental group (primary tumor resections) or Control group (primary tumor resections combined with cholecystectomy). The investigators will follow up patients until week 104 after surgery (8 visits).

Eligibility criteria: Inclusion Criteria:

* Patients must grant the informed consent written, signed and dated.
* Male or female older than 18 years old.
* Radiological or histological diagnose of midgut NET that can be treated with surgery.
* In case of female with childbearing age (time between menarche and menopause), a pregnancy test with negative result.
* Neuroendocrine tumors located in any of the aforementioned locations.
* Presence or not of distant metastasis.
* Presencié or not of gallstones.
* Capacity of follow up.

Exclusion Criteria:

* Neuroendocrine tumors which are not located in jejunum or ileum (bronchial, gastric, pancreatic, descending colon, sigma or rectum.).
* Patients that have gone through a previous bowel resection.
* Patients with previous cholecystectomy.
* Pacients with biliary stone disease.
* Patients who are candidate to liver resection or liver transplant.
* Patients with a gallbladder polyp bigger than 6 mm.
* Pacients with one gallbladder sessile polyp, presence of more than one polyp or patients older than 50 years old with a polyp.
* Refusal to participate.
* Patients with previous history of malignant neoplasms in the last 5 years, except skin basal cell carcinoma, "in situ" cervical carcinoma or in situ carcinoma found in a polyp removed with a colonoscopy.
* Medical criteria that doesn't consider the patient a candidate to participate in the study.

Primary outcomes:
measure: To evaluate the rate of biliary stone disease associated to patients with midgut NET that have gone through primary tumor surgery.
timeFrame: Two years after the surgery
Secondary outcomes:
measure: To assess the incidence of post-operative complications until day 28 +/- 3 (1 Month) after the surgery.
timeFrame: One month after the surgery
measure: To assess the incidence of: anastomotic dehiscence, wound infection, reoperation.
timeFrame: One month after the surgery
measure: To evaluate the incidence of gallstone in patients who require a bowel resection and/or ileocecal junction resection.
timeFrame: Two years after the surgery
measure: To evaluate de incidence of gallstones in patients who will receive medical treatment with SSA
timeFrame: Two years after the surgery
measure: To describe bowel movements of patients after the surgery.
timeFrame: Two years after the surgery
measure: To compare quality of life in patients who went through a prophylactic cholecystectomy against those who did not.
timeFrame: Two years after the surgery
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: Hospital Universitari Trias i Pujol
state: Barcelona
city: L'Hospitalet De Llobregat
country: Spain
facility: Instituto Catalán de Oncología
state: Barcelona
city: Barcelona
country: Spain
facility: IDIBELL, Hospital Universitari de Bellvitge.
city: Barcelona
country: Spain
facility: Hospital del Mar
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron
city: Madrid
country: Spain
facility: Hospital Universitario Gregorio Marañón
Study officials:
affiliation: Hospital Universitari de Bellvitge
name: Ricardo Frago Montanuy
role: PRINCIPAL_INVESTIGATOR
References: